Literature DB >> 10354150

A new preconditioning regimen with melphalan, busulphan and total body irradiation followed by low-dose immunosuppressant in allogeneic haemopoietic stem cell transplantation.

M Murata1, T Nishida, M Haneda, T Kanie, H Taji, H Iida, R Suzuki, M Hamaguchi, S Minami, Y Kodera.   

Abstract

Twenty adult patients with high-risk leukaemia underwent allogeneic haemopoietic stem cell transplantation after melphalan, busulphan and total body irradiation followed by short-term methotrexate and low-dose cyclosporine or tacrolimus. Three patients developed veno-occlusive disease and no patient developed renal dysfunction. Seven patients experienced grade II-IV acute graft-versus-host disease (aGVHD) and five patients experienced grade III-IV. The 3-year probabilities of relapse and leukaemia-free survival were 22 +/- 11% (95% confidence interval) and 50 +/- 11%, respectively. These data suggest that this preconditioning regimen followed by a low-dose immunosuppressant provided a more anti-leukaemic effect without increased regimen-related toxicity and aGVHD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10354150     DOI: 10.1046/j.1365-2141.1999.01424.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

1.  Long-term outcomes of allogeneic hematopoietic cell transplantation with intensified myeloablative conditioning for refractory myeloid malignancy.

Authors:  N Kawashima; Y Inamoto; T Sato; M Nakashima; Y Kagaya; K Watakabe; A Seto; N Fukushima; S Kurahashi; Y Ozawa; K Miyamura
Journal:  Bone Marrow Transplant       Date:  2016-02-15       Impact factor: 5.483

2.  Single center experience with total body irradiation and melphalan (TBI-MEL) myeloablative conditioning regimen for allogeneic stem cell transplantation (SCT) in patients with refractory hematologic malignancies.

Authors:  Bhavana Bhatnagar; Aaron P Rapoport; Hong-Bin Fang; Can Ilyas; Deniz Marangoz; Vinil Akbulut; Kathleen Ruehle; Ashraf Badros; Saul Yanovich; Görgün Akpek
Journal:  Ann Hematol       Date:  2013-10-06       Impact factor: 3.673

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.